Active Biotech AB (FRA:BTP) Cyclically Adjusted FCF per Share: €-0.71 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BTP Active Biotech AB FRA:BTP
34 GF Score
Price €0.45
GF Value €0.13
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Active Biotech AB Cyclically Adjusted FCF per Share?

Active Biotech AB FRA:BTP -5.51% 34 Cyclically Adjusted FCF per Share is €-0.71 as of Mar. 2026. GuruFocus rates FRA:BTP with a GF Score™ of 34/100 and a GF Value™ of €0.13 (Significantly Overvalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Active Biotech AB's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.028. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.71 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 28.60% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 19.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Active Biotech AB was 28.60% per year. The lowest was 6.50% per year. And the median was 11.95% per year.

As of today (2026-07-25), Active Biotech AB's current stock price is €0.4455. Active Biotech AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-0.71. Active Biotech AB's Cyclically Adjusted Price-to-FCF of today is .


Active Biotech AB  (FRA:BTP) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Active Biotech AB Cyclically Adjusted FCF per Share Related Terms


Active Biotech AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Active Biotech AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Active Biotech AB Cyclically Adjusted FCF per Share Chart

Active Biotech AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.99 -3.32 -2.16 -2.49 -0.86

Active Biotech AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.31 -1.08 -0.92 -0.86 -0.71

FRA:BTP vs VRTX, REGN, ALNY: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Active Biotech AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Active Biotech AB Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Active Biotech AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Active Biotech AB's Cyclically Adjusted Price-to-FCF falls into.


FRA:BTP
34GF Score
Active Biotech AB FRA:BTP
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Active Biotech AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Active Biotech AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.028/133.5600*133.5600
=-0.028

Current CPI (Mar. 2026) = 133.5600.

Active Biotech AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.407 101.019 -0.538
201609 -0.360 101.138 -0.475
201612 -0.303 102.022 -0.397
201703 -0.376 102.022 -0.492
201706 -0.296 102.752 -0.385
201709 -0.233 103.279 -0.301
201712 -0.191 103.793 -0.246
201803 -0.277 103.962 -0.356
201806 -0.240 104.875 -0.306
201809 -0.139 105.679 -0.176
201812 -0.157 105.912 -0.198
201903 -0.131 105.886 -0.165
201906 -0.208 106.742 -0.260
201909 -0.097 107.214 -0.121
201912 -0.169 107.766 -0.209
202003 -0.194 106.563 -0.243
202006 -0.164 107.498 -0.204
202009 -0.123 107.635 -0.153
202012 -0.078 108.296 -0.096
202103 -0.122 108.360 -0.150
202106 -0.185 108.928 -0.227
202109 -0.135 110.338 -0.163
202112 -0.246 112.486 -0.292
202203 -0.200 114.825 -0.233
202206 -0.200 118.384 -0.226
202209 -0.157 122.296 -0.171
202212 -0.145 126.365 -0.153
202303 -0.121 127.042 -0.127
202306 -0.147 129.407 -0.152
202309 -0.098 130.224 -0.101
202312 -0.122 131.912 -0.124
202403 -0.092 132.205 -0.093
202406 -0.096 132.716 -0.097
202409 -0.063 132.304 -0.064
202412 -0.135 132.987 -0.136
202503 -0.054 132.825 -0.054
202506 -0.052 133.699 -0.052
202509 -0.042 133.480 -0.042
202512 -0.039 133.390 -0.039
202603 -0.028 133.560 -0.028

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.71 mean?
Active Biotech AB (FRA:BTP) has a Cyclically Adjusted FCF per Share of €-0.71 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Active Biotech AB and its competitors.
Is Active Biotech AB's Cyclically Adjusted FCF per Share too high?
Active Biotech AB's current Cyclically Adjusted FCF per Share is €-0.71. Overall, Active Biotech AB has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Active Biotech AB's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Active Biotech AB's Cyclically Adjusted FCF per Share of €-0.71 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Active Biotech AB and its competitors. Active Biotech AB's current Cyclically Adjusted FCF per Share is €-0.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Active Biotech AB stock overvalued right now?
Based on GuruFocus' analysis, Active Biotech AB (FRA:BTP) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.13, compared to a current price of €0.45 — trading 242.7% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €-0.71. Active Biotech AB's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Active Biotech AB (FRA:BTP), the current Cyclically Adjusted FCF per Share is €-0.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Active Biotech AB (FRA:BTP) Overvalued in 2026?

Based on GuruFocus' analysis, Active Biotech AB stock appears to be overvalued. The current stock price of €0.45 is trading 242.7% above its estimated GF Value™ of €0.13. GuruFocus considers Active Biotech AB to be Significantly Overvalued.

Key valuation signals for FRA:BTP:

  • Cyclically Adjusted FCF per Share: €-0.71
  • GF Value™: €0.13 vs. price of €0.45 (242.7% above fair value)
  • GF Score™: 34/100 with 1 warning sign

No single metric tells the full story. See the FRA:BTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Active Biotech AB Business Description

Other Exchanges ACTI:Sweden0GQU:UK
Address Scheelevagen 22, P.O. Box 724, Lund, SWE, 223 63
Active Biotech AB focuses on the research and development of pharmaceuticals products within medical areas including neurodegenerative diseases, autoimmune/inflammatory disease and various forms of cancer. Its project portfolio contains both small molecules that are orally active immunomodulatory agents and antibody based immunotherapy. Its project portfolio includes both small orally active immunomodulatory molecules and antibody-based immunotherapy. Its pipeline products are: Tasquinimod, Laquinimod, and Naptumomab.
34GF Score

Get the complete analysis for FRA:BTP

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.45
Price
€0.13
GF Value